Princeton, NJ, November 6, 2023 (Reuters) -- Bristol Myers Squibb (BMY.N) acquires an experimental therapy to treat a type of blood cancer for an upfront payment of $100 million and a total value of up to $180 million from Orum Therapeutics' a privately held company. The therapy has early stage study clearance from the FDA.
Read full article here.
Durham, NCÂ and Seattle, WA, January 12, 2025 (Business Wire) -- Tune Therapeutics has raised $175 million in Series B funding to...
Ribometrix Names William S. Marshall, Ph.D., as CEO to Drive Breakthrough RNA-Targeting Therapeutics
Durham, NC, January 09, 2025 (Globe newswire) -- Ribometrix has appointed Dr. William S. Marshall as CEO and Dr. Katie Warner as CSO,...
San Francisco & Princeton, NJ, January 10, 2025 (Business Wire) -- Kardigan launches with $300 million in funding and a mission to cure...
Comments